Eli Lilly Develops One-Time Gene Editing Treatment for Cholesterol

Eli Lilly is developing a groundbreaking gene editing treatment aimed at permanently lowering bad cholesterol and reducing the risk of heart disease. According to Bloomberg's Madison Muller, this one-time therapy is part of the company's effort to move beyond obesity drugs and enter a new growth phase. The treatment uses gene editing technology to permanently affect bad cholesterol levels in the body. Unlike current cholesterol medications, this approach aims to provide long-term benefits without requiring patients to undergo continuous treatment. However, gene editing therapies carry significant risks, including potential side effects and long-term safety concerns. Eli Lilly is conducting comprehensive clinical trials to minimize these risks. Following its success in obesity drugs, the company aims to grow in the cardiovascular field as well. This new treatment is part of Lilly's strategy to diversify its drug portfolio and offer an innovative solution to a common health issue like heart disease. This is not investment advice.